ADVISORY, Aug. 6, 2013 (GLOBE NEWSWIRE) -- What: Epizyme, Inc. [EPZM], a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, will visit the NASDAQ MarketSite in Times Square. In honor of the occasion, Dr. Robert Gould, CEO, Jason Rhodes, President and CFO, Dr. Robert Copeland, EVP and CSO, and Dr. Eric Hedrick, CMO, will ring the Closing Bell. Where: NASDAQ MarketSite – 4 Times Square – 43 rd & Broadway – Broadcast Studio When: Wednesday, August 7, 2013 – 3:45 p.m. to 4:00 p.m. ET Contact : Stephanie Ascher (212) 362-1200 firstname.lastname@example.org NASDAQ MarketSite: Christine Barna (646) 441-5310 Christine.Barna@nasdaqomx.com Feed Information: Fiber Line (Encompass Waterfront): 4463 Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC 3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK Facebook and Twitter: For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at: http://www.facebook.com/NASDAQ . For news tweets, please visit our Twitter page at: http://twitter.com/nasdaqomx . Webcast: A live webcast of the NASDAQ Closing Bell will be available at: http://www.nasdaq.com/about/marketsitetowervideo.asx . Photos: To obtain a hi-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice. About Epizyme, Inc. [EPZM]: Epizyme, Inc. is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers. Epizyme has built a proprietary product platform that the company uses to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing). By focusing on the genetic drivers of cancers, Epizyme's targeted science seeks to match the right medicines with the right patients for a personalized approach to cancer treatment.